Percutaneous RVAD to Preemptively Treat Right Heart Failure Post-LVAD

A trial with no phase registered on ClinicalTrials.gov. The registry status is terminated. It enrolled 161 participants.

Also called NCT04458103

  • Study
  • In this atlas

Overview

Design
Interventional study; non-randomized; no masking; primary purpose prevention
Phase
Not applicable
Enrolled
  • 161 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT04458103
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States (from the registry)
Registry status
  • Terminated (from the registry)

Technical summary

Registry record NCT04458103. Non-randomized; no masking; primary purpose prevention. Start 2020-05-12 (actual); primary completion 2022-06-01 (actual). Results posted on 2024-07-09.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Percutaneous RVAD to Preemptively Treat Right Heart Failure Post-LVAD
Condition
Heart Failure
Intervention (Device)
Percutaneous RVAD
Lead sponsor
Massachusetts General Hospital (class: other)

Record details

Record id
cardio:ct-nct04458103
Content hash
ae334fa4c31afda3d108cd298788f07015f3bdebb3b0d6eec77ea8a125cca1a2